Citations

Clear

9383 citation(s) found for "Thomas, PS".

Glomerular pathology of vascular endothelial growth factor inhibition—A 12-year review at the Mayo Clinic
Chowdhury, Raad , Mohan, A. , Mignano, Salvatore , Alexander, Mariam P., Buglioni, Alessia , Herrmann, Sandra M. , Herrmann, Sandra M , Mohan, Arjunmohan , Buglioni, Alessia , Charkviani, Mariam

Mayo Clinic

Journal of Onco-Nephrology | August 1, 2025 | Volume: 9 | Issue: 3 | Pages: 51-61

10.1177/23993693251356093 Get It

Background: Vascular endothelial growth factor inhibitors (VEGF-I) are frequently used for cancer treatment. VEGF-I can cause proteinuria and acute kidney injury (AKI) with thrombotic microangiopathy (TMA) as a commonly described pathology, but other glomerular pathologies are not well characterized. We aim to describe the clinical characteristics and glomerular lesions associated with VEFG-I in a single center cohort. Methods: We performed a retrospective chart review of patients treated with VEGF-I and underwent kidney biopsies from 2010 to 2022 at the Mayo Clinic, Rochester, MN. Biopsy findings were reviewed by our pathologists. Data on patients’ characteristics, clinical course, and outcomes were abstracted. Descriptive statistics were used to report relevant patient characteristics and findings. Results: From 2010 to 2022, 19 kidney biopsies were performed for kidney dysfunction in patients on VEGF-I. Eleven had complete data, with a median age of 62 years (interquartile range 58–66 years); renal cell carcinoma (RCC) was the most common cancer (4 of 11 patients). TMA was noted in 8 of the 11 biopsies, with proteinuria as the most frequent indication for biopsy in these cases. Three patients had findings other than TMA. One developed anti-phospholipase A2 receptor negative membranous nephropathy; VEGF-I and pembrolizumab were discontinued, and prednisone improved proteinuria. Another patient had known cryoglobulinemia with nephrotic range proteinuria which was exacerbated by VEGF-I peaking at 11 g/day. Despite stopping VEGF-I and treating with prednisone and rituximab, kidney dysfunction progressed to end stage kidney disease (ESKD). A third patient had IgA nephropathy with concurrent diabetic changes, but proteinuria progressed even after stopping VEGF-I. Conclusion: In this case-series of patients treated with VEGF-I undergoing kidney biopsy, we describe the pathological characteristics, clinical course, and outcomes of patients with pathologies other than TMA. Our study adds information to the sparse literature on patients with renal dysfunction after receiving VEGF-I.
Predicting Symptomatic Response to Prokinetic Treatment Using Gastric Alimetry
Varghese, Chris , Hove, Sibylle Van, Schamberg, Gabriel , Wu, Billy, Poonawala, Nooriyah, Law, Mikaela , Dachs, Nicky , Johnston, Gen, Fitt, India, Foong, Daphne , Andrews, Christopher N. , O’Grady, Gregory , Parkman, H P , Abell, T L , O'Grady, Gregory , Varghese, Chris , Schamberg, Gabriel , Johnston, Gen, Parkman, Henry P. , Abell, Thomas L. , Ho, Vincent , Calder, Stefan , Gharibans, Armen A. , Andrews, Christopher N.

Mayo Clinic

Neurogastroenterology & Motility | July 30, 2025 | Volume: 37 | Issue: 11 | Pages: No page available

10.1111/nmo.70132 | PMID 40734520 Get It

ABSTRACT Background Chronic neurogastroduodenal disorders are challenging to manage, with therapy often initiated on a trial and error basis. Prokinetics play a significant role in management, but responses are variable and have been associated with adverse events, impacting widespread use. We investigated whether body surface gastric mapping (BSGM) biomarkers (using Gastric Alimetry) could inform patient selection for prokinetic therapy. Methods Patients with chronic gastroduodenal symptoms taking oral prokinetic agents, regardless of gastric emptying status, were prospectively recruited and underwent BSGM (30 m baseline, 482 kcal standardized meal, 4 h postprandial recording) while off‐prokinetic agents. Patients were followed up with daily symptom diaries. A subset was compared to matched patients not taking prokinetic agents. Prokinetic responders were defined based on symptom improvement greater than a minimum clinically important difference methodology. Key Results Forty‐two patients (88% female; median age 36; median BMI 26) taking prokinetics were analyzed. Prokinetic prescribing, compared to matched patients, was independent of BSGM metrics ( p > 0.15). In patients on existing prokinetics (withheld for BSGM), lower amplitudes predicted reduced symptom burden, whereas low rhythm stability predicted a worse symptom burden ( p < 0.05). In prokinetic‐naive patients (i.e., started on a prokinetic during the study), a lower postprandial amplitude predicted responders (mean 37.5 ± 10.6 uV in responders [ n = 5] vs. mean 54.8 ± 6.6 uV among nonresponders [ n = 3], p = 0.047). Conclusions Gastric Alimetry biomarkers may help in the prediction of prokinetic response in patients with chronic gastroduodenal symptoms. Lower postprandial amplitudes, indicating a reduced meal response, appear to predict benefit, while impaired rhythm stability predicted poorer therapeutic response.
Exploring Risk and Protective Factors: Understanding Nonmedical Stimulant Use Among Florida High School Students
Hamadi, Hanadi , Thomas, Rachel McMahan, Xie, Zhigang, Patterson, Karen B., Spaulding, Aaron, Spaulding, Aaron , Spaulding, Aaron , Hamadi, Hanadi Y , Thomas, Rachel McMahan, Xie, Zhigang, Patterson, Karen B.

Mayo Clinic

Journal of Drug Issues | July 29, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/00220426251364375 Get It

Nonmedical stimulant use (NMSU) among adolescents poses significant public health concerns. Using cross-sectional design, this study examined risk and protective factors for NMSU among 20,576 Florida high school students using the 2020 Florida Youth Substance Abuse Survey, with 925 students reporting NMSU. Guided by Hawkins and Catalano’s Social Development Model, we employed multivariate logistic regression analyses to estimate adjusted odds ratios while controlling for demographics. Students engaged in extracurricular activities were 50% less likely to report NMSU. Higher academic performance was associated with lower NMSU likelihood. Students with friends who used stimulants nonmedically were significantly more likely to engage in NMSU (AOR, 7.60; 95% CI: 6.35, 9.10), as were those living with relatives who used substances (AOR, 3.54; 95% CI: 2.94, 4.26). Findings highlight the importance of extracurricular involvement and positive social networks in mitigating NMSU. Interventions addressing family, peers, and extracurricular involvement are crucial for prevention and evidence-based policies.
Alzheimer's Association Clinical Practice Guideline on the use of blood‐based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings
Whitson, Heather E. , Allen, Laura A., Galasko, Douglas, Okrahvi, Hamid R., Paczynski, Madeline , Carrillo, Marı́a C., Edelmayer, Rebecca M. , McAteer, Mary Beth , Pahlke, Sarah , Tampi, Malavika P. , Carrillo, María C. , Palmqvist, Sebastian , Suárez‐Calvet, Marc , Karikari, Thomas K. , Schindler, Suzanne E. , Teunissen, Charlotte E. , Zetterberg, Henrik , Mahinrad, Simin , Kahale, Lara A

Mayo Clinic

Alzheimer's & Dementia | July 29, 2025 | Volume: 21 | Issue: 7 | Pages: No page available

10.1002/alz.70535 | PMID 40729527 Get It

Abstract OBJECTIVE AND SCOPE A panel of clinicians, subject‐matter experts, and guideline methodologists convened by the Alzheimer's Association conducted a systematic review and formulated evidence‐based recommendations for using blood‐based biomarkers (BBMs) in the diagnostic workup of suspected Alzheimer's disease (AD) within specialized care settings. The scope focuses on individuals with objective cognitive impairment, including those with mild cognitive impairment (MCI) or dementia, who are undergoing evaluation by providers trained and experienced in memory disorders, where AD is the suspected underlying etiology. METHODS The panel conducted a systematic review to assess the diagnostic accuracy of BBMs in detecting AD pathology. The BBMs of interest included plasma phosphorylated‐tau (p‐tau) and amyloid‐beta (Aβ) tests measuring the following analytes: p‐tau217, ratio of p‐tau217 to non‐p‐tau217 ×100 (%p‐tau17), p‐tau181, p‐tau231, and ratio of Aβ42 to Aβ40. The reference standard tests included cerebrospinal fluid (CSF) AD biomarkers, amyloid positron emission tomography (PET), or neuropathology. The panel applied the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach to assess the certainty of the evidence and the GRADE evidence‐to‐decision (EtD) Framework to develop its recommendations. RECOMMENDATIONS The key recommendations in this Clinical Practice Guideline (CPG) are: (1) BBM tests with ≥90% sensitivity and ≥75% specificity can be used as a triaging test and (2) BBM tests with ≥90% sensitivity and specificity can serve as a substitute for amyloid PET imaging or CSF AD biomarker testing in patients with cognitive impairment presenting to specialized care for memory disorders. The panel cautions users of this guideline that there is significant variability in diagnostic test accuracy and many commercially available BBM tests do not meet these thresholds, especially using a single cutoff. Additionally, these tests do not serve as a substitute for comprehensive clinical evaluation by a healthcare professional and should be used only as part of a full diagnostic workup of patients with cognitive impairment presenting to specialized care settings, and with careful consideration of pretest probability of AD pathology. CONCLUSIONS AND PRACTICAL IMPLICATIONS This CPG provides performance‐based, brand‐agnostic recommendations for the use of BBMs in the diagnostic workup of suspected AD within specialized care settings. By linking recommendations to a systematic review and associated living updates, and using a robust and transparent methodology, the guideline ensures scientific rigor, adaptability, and sustained relevance as evidence evolves. Clinicians are encouraged to stay informed about emerging paradigms—such as biomarker combinations or ratios and multi‐threshold testing—that may further refine the diagnostic accuracy of BBMs as the field evolves.
Letter to the Editor regarding ‘Evaluating nurse preferences for a novel on-body delivery system vs. manual syringes for large-volume subcutaneous drug administration: a survey study’
Desai, Mehul , Gorski, Lisa A., Miles, A. , Sterlin, Valentina, Curry, Nicole, Faiman, Beth M , Miles, Ashley, Curry, Nicole

Mayo Clinic

Drug Delivery | July 29, 2025 | Volume: 32 | Issue: 1 | Pages: No page available

10.1080/10717544.2025.2537818 | PMID 40726334 Get It

Intercostal Nerve Cryoablation During Pectus Excavatum Surgery for Postoperative Pain Management
Notrica, David M. , McMahon, Lisa , Hahn, A. , Ndikintum, Nfii, Dua, Madelyn, Jaroszewski, Dawn E. , McMahon, Lisa E , Hahn, Alyssa , Dua, Madelyn

Mayo Clinic

Annals of Surgery | July 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000006855 | PMID 40720602 Get It

Objective: The objective of this study was to systematically review the literature-reported outcomes of CRYO compared to standard of care without CRYO (non-CRYO) after PEx repair. Summary Background Data: Surgical repair of pectus excavatum (PEx) via the Nuss or Ravitch procedures is associated with substantial postoperative pain. Intercostal nerve cryoablation (CRYO) performed during the primary surgical repair has been adopted as a non-opioid modality for pain management. Methods: A literature search was conducted in PubMed, Embase, and using additional online approaches to identify comparative studies of patients undergoing the Nuss or Ravitch procedure for PEx repair with CRYO versus non-CRYO between years 2014-24. Meta-analysis was performed to quantitatively evaluate primary outcomes of hospital length of stay (LOS) and opioid consumption. Secondary outcomes were hospital costs and complications, summarized qualitatively. Results: Of 178 studies, 32 comparative studies encompassing 13,103 patients were included; 28% (n=3,620) received CRYO. Random effects meta-analyses demonstrated a significantly shortened LOS by 1.8 days (95% confidence interval [CI]: -2.12, -1.42) and a significant reduction in inpatient and outpatient opioid consumption with CRYO by 186 morphine mg equivalents (MME) (95% CI: -262.26, -109.08) and 147 MME (95% CI: -255.72, -38.26), respectively. Complications with CRYO were either decreased or similar between groups and resolved over time. Hospital costs were similar. Conclusions: This systematic review suggests CRYO during PEx repair is associated with a significantly shorter hospital LOS, as well as decreased opioid consumption both in the hospital and after discharge. Complications were infrequent and time-limited.
Treatment Trends and Outcomes of Endovascular versus Open Thoracoabdominal Aortic Aneurysm Repair – A Single-center Comparative Cohort Study
Huang, Ying , Colglazier, Jill J. , Pochettino, Alberto , Kalra, Manju , Bower, Thomas C., Greason, Kevin L. , Mendes, Bernardo C. , Harmsen, William S. , Colglazier, Jill , Oderich, Gustavo S , Tenorio, Emanuel R. , Gloviczki, Péter , Oderich, Gustavo S.

Mayo Clinic

Annals of Surgery | July 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000006848 | PMID 40720611 Get It

Objective: To evaluate treatment trends and compare outcomes following fenestrated-branched endovascular aortic repair (FB-EVAR) versus open surgical repair (OSR) of thoracoabdominal aortic aneurysms (TAAA). Background: FB-EVAR has been increasingly utilized as a less invasive alternative to OSR for treatment of TAAAs. Methods: We studied patients who underwent elective FB-EVAR or OSR of TAAAs (2008-2020), since the initiation of an Advanced Endovascular Aortic Program. Primary endpoints were early major adverse events (MAE) and early and late all-cause mortality. Propensity score overlap weighting analysis was performed to adjust for measured confounders between groups. Results: There were 357 (70.8%) patients treated by FB-EVAR and 147 (29.2%) with OSR. The use of FB-EVAR increased from 16.7% in 2008 to >80% since 2017 ( P <0.001). Incidences of early MAEs were 25.8% and 49.0%, respectively; early mortality rates for FB-EVAR and OSR were 2.5% and 6.8%, respectively. In the weighted cohort, FB-EVAR patients had decreased early MAEs (weight-adjusted odds ratio [aOR], 0.28; 95% confidence interval [CI], 0.18-0.41; P <0.001) and mortality (aOR, 0.35; 95% CI, 0.17-0.73; P =0.005) versus OSR patients. Five-year survival estimates were 52.2% (95% CI, 45.2-60.4%) and 78.0% (95% CI, 70.6-86.2%), respectively. In the weighted cohort, there was no significant difference in late survival between groups (weight-adjusted hazard ratio, 1.33; 95% CI, 0.74-2.39; P =0.34). Conclusions: This study confirmed the change in practice from OSR to FB-EVAR for treatment of TAAAs over the past decade. Incidences of early MAEs and mortality were lower with FB-EVAR, with no significant difference in late survival in the weighted cohort.
Unravelling the myriad physiologic roles of transthyretin: critical considerations for treating transthyretin amyloidosis
Gertz, Morie A. , Aras, Mandar A. , Bart, N. , Brannagan, Thomas H., Griffin, Jan M. , Kontorovich, Amy , Rosen, Andrew M. , Kontorovich, Amy R , Gertz, Morie A , Brannagan, Thomas H.

Mayo Clinic

Annals of Medicine | July 28, 2025 | Volume: 57 | Issue: 1 | Pages: No page available

10.1080/07853890.2025.2536755 | PMID 40717228 Get It

Midlife Retinal Microvascular Signs and Late-Life Neuroimaging Features of Cerebral Small Vessel Disease in the ARIC Study
Jiang, Kening , Power, Melinda C. , Bandeen‐Roche, Karen , Griswold, Michael , Albert, Marilyn , Knopman, David S. , Mosley, Thomas H. , Walker, Keenan A. , Sharrett, A. Richey, Egle, Marco , Mosley, Thomas H. , Knopman, David S. , Griswold, Michael , Albert, Marilyn S. , Gottesman, Rebecca F , Egle, Marco , Deal, Jennifer A , Walker, Keenan A , Gottesman, Rebecca F. , Deal, Jennifer A.

Mayo Clinic

Neurology | July 25, 2025 | Volume: 105 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000213919 | PMID 40712116 Get It

Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
Kirthika, Perumalraja , Jawalagatti, Vijayakumar , Li, Peiyao , Xu, Michael , Carceles‐Cordon, Marc , Ertel, Adam , Quinn, S. Aidan , Petrylak, Daniel P. , Orme, Jacob J. , Dehm, Scott M. , Heath, Elisabeth I. , Cordon‐Cardo, Carlos , Zhu, Shijia , Domingo‐Domenech, Josep , Rodríguez-Bravo, Verónica , Antonarakis, Emmanuel S , Heath, Elisabeth I , Pandey, Mukesh K , Cordon-Cardo, Carlos , Huang, Rui , Dong, Haidong , Zhu, Shijia , Domingo Domenech, Josep M , Rodriguez-Bravo, Veronica , Dehm, Scott M , Kirthika, Perumalraja , Jawalagatti, Vijayakumar , Antonarakis, Emmanuel S. , Pandey, Mukesh K. , Huang, Haojie , Dong, Haidong

Mayo Clinic

Cancer Discovery | July 25, 2025 | Volume: 15 | Issue: 11 | Pages: 2374-2396

10.1158/2159-8290.cd-25-0629 | PMID 40709833 Get It

Abstract The roles of nucleoplasm-residing nucleoporins (NUP) in solid tumors, including prostate cancer, remain unknown. In this study, we reveal the clinical significance and mechanistic role of the off-pore NUP, soluble POM121 (sPOM121), as a crucial transcriptional regulator that enhances the aggressiveness of metastatic prostate cancer. Using orthogonal methodologies in human samples, sPOM121 was identified as the predominantly expressed nucleoplasmic NUP in prostate cancer. Unbiased proteomic and epigenomic studies demonstrate that sPOM121, through its C-terminus, interacts with the chromatin remodeler SMARCA5 at gene promoter sites and localizes at nuclear condensates, reprogramming gene expression. Indeed, sPOM121 regulates a distinct oncogenic gene network, including β-catenin, leading to prostate cancer progression and immune evasion. Importantly, targeting the sPOM121/β-catenin axis in patient-derived preclinical and syngeneic mouse models halts prostate cancer aggressiveness and enhances antitumor immunity. Taken together, these findings reveal previously unknown actionable reprogramming functions of off-pore NUPs in solid tumors. Significance: This study uncovers how oncogenic signaling programs are transcriptionally heightened by the NUP sPOM121 in metastatic prostate cancer. Localization of sPOM121 at active transcriptional nuclear condensates propels disease progression and immune evasion, offering novel anticancer therapeutic opportunities.